Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532399 · ClinicalTrials.gov registry record
Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation
A clinical trial of Drug Effect, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT03532399 is a study of Drug Effect that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03532399, a study of Drug Effect, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will measure plasma concentrations of bivalirudin in pediatric patients undergoing cardiac catheterization, cardiac surgical procedures utilizing cardiopulmonary bypass (CPB), or extracorporeal support with ECMO, ventricular support devices (VAD) or lung-assist devices (LAD). The aim is to understand the pharmacokinetics of bivalirudin in these settings.
Conditions Studied
Interventions
- DRUG Bivalirudin
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2026-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03532399
The ClinicalTrials.gov registry entry for NCT03532399 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Effect appearing as the primary indexed condition, and to 1 intervention - of which Bivalirudin is the first listed.
NCT03532399 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03532399 about?
NCT03532399 is a clinical study titled "Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation". This study will measure plasma concentrations of bivalirudin in pediatric patients undergoing cardiac catheterization, cardiac surgical procedures utilizing cardiopulmonary bypass (CPB), or extracorporeal support with ECMO, ventricular support devices (VAD) or lung-assist devices (LAD). The aim is t...
What is the current status of trial NCT03532399?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2018-07-12. Estimated completion is 2026-05.
What conditions does trial NCT03532399 study?
This clinical trial studies the following conditions: Drug Effect.
What interventions are being tested in trial NCT03532399?
The interventions under investigation include: Bivalirudin (DRUG).
Who is sponsoring clinical trial NCT03532399?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03532399 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Effect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.